Results 21 to 30 of about 2,733 (199)

Tecovirimat Resistance in Mpox Patients, United States, 2022–2023

Emerging Infectious Diseases, 2023
During the 2022 multinational outbreak of monkeypox virus (MPXV) infection, the antiviral drug tecovirimat (TPOXX; SIGA Technologies, Inc., https://www.siga.com) was deployed in the United States on a large scale for the first time.
Todd G. Smith, Crystal M. Gigante, Nhien T. Wynn, Audrey Matheny, Whitni Davidson, Yong Yang, Rene Edgar Condori, Kyle O’Connell, Lynsey Kovar, Tracie L. Williams, Yon C. Yu, Brett W. Petersen, Nicolle Baird, David Lowe, Yu Li, Panayampalli S. Satheshkumar, Christina L. Hutson   +16 more
doaj   +1 more source

Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report

Vaccines, 2023
Purpose: To report a case of severe mpox in a newly diagnosed HIV patient concerning for Immune Reconstitution Inflammatory Syndrome (IRIS) and/or tecovirimat resistance and to describe the management approach in the setting of refractory disease.
Andres E. Martinez, Paola Frattaroli, Christine A. Vu, Lizy Paniagua, Joel Mintz, Andres Bravo-Gonzalez, Paola Zamudio, Astrid Barco, Aruna Rampersad, Paola Lichtenberger, Jose A. Gonzales-Zamora   +10 more
doaj   +1 more source

The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review

International Journal of Infectious Diseases, 2023
Objectives: Human monkeypox virus (MPXV) infection is a recently declared public health emergency of international concern by the World Health Organization. Besides, there is scant literature available on the use of antivirals in MPXV infection.
Muhammad Aaqib Shamim, Bijaya Kumar Padhi, Prakasini Satapathy, Sai D Veeramachaneni, Chandrima Chatterjee, Snehasish Tripathy, Naushaba Akhtar, Anindita Pradhan, Pradeep Dwivedi, Aroop Mohanty, Alfonso J. Rodriguez-Morales, Ranjit Sah, Ala'a B. Al-Tammemi, Jaffar A. Al-Tawfiq, Behdin Nowrouzi-Kia, Vijay Kumar Chattu   +15 more
doaj   +1 more source

Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox

BMJ Open, 2023
Introduction Monkeypox was originally endemic locally in West Africa; however, outbreaks in non-endemic countries have been recognised since May 2022.
Norio Ohmagari, Sho Saito, Shinya Tsuzuki, Tetsuya Suzuki, Shinobu Ashida, Mizue Takakusaki, Tomoki Yoshikawa, Masayuki Shimojima, Hideki Ebihara, Shinichiro Morioka   +9 more
doaj   +1 more source

Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection.

PLoS Biology, 2023
Despite use of tecovirimat since the beginning of the 2022 outbreak, few data have been published on its antiviral effect in humans. We here predict tecovirimat efficacy using a unique set of data in nonhuman primates (NHPs) and humans.
Bach Tran Nguyen, Aurélien Marc, Clara Suñer, Michael Marks, Maria Ubals, Águeda Hernández-Rodríguez, María Ángeles Melendez, Movie Group, Dennis E Hruby, Andrew T Russo, France Mentré, Oriol Mitjà, Douglas W Grosenbach, Jérémie Guedj   +13 more
doaj   +1 more source

Navigating the expanded access investigational new drug protocol for tecovirimat: lessons learned from a public–private hospital partnership during the 2022 NYC mpox outbreak

Antimicrobial Stewardship & Healthcare Epidemiology, 2023
During the 2022 mpox outbreak, tecovirimat was accessed through an expanded access investigational new drug (EA-IND) protocol. We leveraged a unique public/private hospital partnership in New York City to create a novel infrastructure to navigate the EA ...
Ofole Mgbako, Justin Chan, Robert A. Pitts, Madeline A. DiLorenzo, Dorothy Knutsen, Dana Mazo   +5 more
doaj   +1 more source

Clinical Features, Antiviral Treatment, and Patient Outcomes:A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox Outbreaks [PDF]

, 2023
Background:This study aims to comparatively analyze clinical features, treatment, and patient outcomes between the previous and the 2022 mpox (monkeypox) outbreaks.
Avan, Amine, Ayada, Ibrahim, de Vries, Annemarie C., Li, Jiajing, Li, Pengfei, Pan, Qiuwei, Peppelenbosch, Maikel P., Zheng, Qinyue   +7 more
core   +2 more sources

Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022

Emerging Infectious Diseases, 2023
Reports of tecovirimat-resistant mpox have emerged after widespread use of antiviral therapy during the 2022 mpox outbreak. Optimal management of patients with persistent infection with or without suspected resistance is yet to be established. We report
Caitlin A. Contag, Leah Mische, Isabel Fong, Abraar Karan, Akanksha Vaidya, David W. McCormick, William Bower, Jill K. Hacker, Kelly Johnson, Perla SanJuan, Linda Crebbin, Caroline Temmins, Harleen Sahni, Yael Bogler, Joseph D. Cooper, Supriya Narasimhan   +15 more
doaj   +1 more source

Fragment-Based Approaches Identified Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13 Protein of the Monkeypox Virus

Viruses, 2023
Monkeypox is a serious public health issue in tropical and subtropical areas. Antivirals that target monkeypox proteins might lead to more effective and efficient therapy. The F13 protein is essential for the growth and maturation of the monkeypox virus.
Yasir Ali, Hina Imtiaz, Muhammad Mutaal Tahir, Fouzia Gul, Umair Ali Khan Saddozai, Ashfaq ur Rehman, Zhi-Guang Ren, Saadullah Khattak, Xin-Ying Ji   +8 more
doaj   +1 more source

Unknown Rectal Lesions: A Case of Severe Proctitis Secondary to Mpox in the Setting of Concomitant HIV, Syphilis, HSV, and Chlamydia [PDF]

, 2023
Introduction: Mpox emerged as a public health crisis with limited research describing co-occurring HIV and sexually transmitted infections (STIs). We present a case of severe proctitis secondary to Mpox with concomitant HIV (Human Immunodeficiency Virus),
Crosby, James, DO, Robertson, Nicole, MPH, Sayers, Anne E., MD, Van Sickles, Nicholas J., MD, Young, Cynthia R., MD, MSc   +4 more
core   +2 more sources